The purpose of this research study is to:
- Test the safety and effectiveness of the study drug, INS068
- Compare the study drug (INS068) to insulin degludec (Tresiba®)
Anticipated date that enrolment will close: end October 2021
NASH is an advanced form of non-alcoholic fatty liver disease that belongs to the most common liver diseases in developed countries. It occurs when fat is deposited in the liver (steatosis), the liver becomes inflamed (hepatitis) and this leads to scar formation in the liver (fibrosis). The research study is testing a potential new treatment for NASH. The new treatment is called BI 456906.
The purpose of this study is to:
- Test the effect of three different doses of the study drug called BI 456906, given one time a week by an injection under the skin in participants with NASH and fibrosis.
- Test the safety, tolerability (side effects) and effectiveness of the study drug BI 456906 compared to placebo (placebo is a substance that looks like the study drug but contains no active drug) in participants with NASH and fibrosis.
Anticipated date that enrolment will close: 30 June 2022
In this research project we are testing a new treatment for mild to moderate active ulcerative colitis. The new treatment is called KBL697 (the study drug) a type of bacteria, called Lactobacillus gasseri. The study aims to learn how effective and safe the drug is in the treatment of people with mild to moderate active ulcerative colitis.
Anticipate date that enrolment will close: August 2026
Currently there is no treatment available to change the course of Huntington's Disease (HD). Everyone with HD has a mutation or change in their DNA that leads to the formation of an abnormal protein that researchers think is toxic or harmful to the brain and is directly involved with causing the symptoms of HD.
This study is designed to see if the administration of an investigational drug, called an antisense oligonucleotide, that is intended to reduce this abnormal protein and is hoped to reduce the rate of progression of the symptoms of HD. Unlike some other clinical studies, this study hopes to only reduce the abnormal protein that the HD gene makes but not the normal protein that may be important for brain function.
Our goal is to determine if the study drug, WVE-003, is safe and well tolerated in the treatment of this disease when compared with a placebo control (dummy treatment that contains no active ingredients).
Anticipated date that enrolment will close: Early 2022
“Point-of-care” (PoC) testing allows diagnoses in the clinic, an ambulance, the home, the field, or in hospital.
The results of point of care testing allow rapid clinical management of the patient. PoC tests are critically needed in remote settings, especially in low-middle income countries, where people may need to travel great distances for healthcare. At ZiP Diagnostics, we are developing PoC diagnostic tests for a range of infectious diseases. For our test development, we require the use of human samples such as swabs, blood and urine. Samples collected for this study will have bacteria or viruses added to then use as known positive samples.
Anticipated date that enrolment will close: 30 April 2022
The purpose of this study is to assess the efficacy and safety of Etrasimod in participants with moderately active ulcerative colitis (UC).
Etrasimod is an experimental treatment. This means that it is not approved treatment for UC by Regulatory Authorities such as the Therapeutic Goods Administration (TGA) in Australia and the Food and Drug Administration (FDA) in America.
Etrasimod is designed to block the movement of some kind of cells in your body (part of your immune system called lymphocytes) to areas of inflammation in the colon.
Anticipated date that enrolment will close: 31 December 2026
Geographic atrophy (GA) is a late stage of age-related macular degeneration (AMD) and occurs when cells in the retina deteriorate and die, resulting in blind spots in the visual fields.
GOLDEN is a study of a potential new treatment referred to as ISIS 696844, or “investigational drug” to determine its safety and effectiveness in slowing the progression of GA caused by AMD.
The investigational drug will be administered via subcutaneous injection beneath the skin in abdomen or thigh—not into the eye. Because of this, there is the potential to treat both eyes with just one single injection.
The total amount of time you could be in the study is approximately 18 months if you complete all parts of the study. There are three periods to the study. First the screening period (14 weeks). If you have been found suitable and undergo the treatment, this will occur over a 12-month period at The Royal Melbourne Hospital. Lastly, there will be a 2-month safety period.
Anticipated date that enrolment will close: Ongoing
Age-related macular degeneration, or AMD, is an eye condition that can cause blurry vision or dark spots when looking straight ahead. Wet AMD occurs when abnormal blood vessels grow under the macula and retina, a part of the eye that helps to see. The abnormal blood vessels leak blood and fluid, causing problems with vision.
The ShORe trial aims to determine if the investigational medication OPT-302 will improve vision for people with wet AMD when given in combination with another medication named ranibizumab, compared to ranibizumab alone.
The total amount of time you could be in the study is almost 2 years if you complete all parts of the study. The trial has 3 parts; screening period of 2 weeks to see if you are eligible. The treatment period which will be about 1 year and 10 months, then a 4-week safety visit after your last dose.
Anticipated date enrolment will close: TBC